Search Results

Showing results 3001 - 3010 for Weill Cornell patient portal

Canadian Hemophilia Society | Comprehensive Hemophilia Treatment Center

...Portal Events Contact Us Weill Cornell Medicine Comprehensive Hemophilia Treatment Center 525 East...

https://hemophilia.weill.cornell.edu/guidelines/canadian-hemophilia-society

National Hemophilia Foundation (NHF) | Comprehensive Hemophilia Treatment Center

...Portal Events Contact Us Weill Cornell Medicine Comprehensive Hemophilia Treatment Center 525 East...

https://hemophilia.weill.cornell.edu/guidelines/national-hemophilia-foundation-nhf

World Federation of Hemophilia (WHF) | Comprehensive Hemophilia Treatment Center

...Portal Events Contact Us Weill Cornell Medicine Comprehensive Hemophilia Treatment Center 525 East...

https://hemophilia.weill.cornell.edu/guidelines/world-federation-hemophilia-whf

Proneurotrophins as Targets for Treatments for CNS Trauma | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/proneurotrophins-targets-treatments-cns-trauma

Synthesis of RNAs Containing Methylated Adenosine Residues and Their Use in Enhancing Translation | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/synthesis-rnas-containing-methylated-adenosine

Methods for the Efficient Identification of Ubiquitination Sites by Proteomics | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/methods-efficient-identification-ubiquitination

Novel Target and Inhibitors for prevention and treatment of Tuberculosis | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/novel-target-and-inhibitors-prevention-and

Training a Machine Learning Network in the Presence of Weak or Absent Training Exemplars to Capture Group Intelligence | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/training-machine-learning-network-presence-weak-or

Use of Dabco-Based Compounds as Potassium Channel Blockers and Openers | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/use-dabco-based-compounds-potassium-channel

Improved Cell Culture Media for the Derivation and Maintenance of Murine Embryonic Stem Cells | Enterprise Innovation

...With a legacy of putting patients first, Weill Cornell Medicine is committed to providing exemplary and...

https://innovation.weill.cornell.edu/industry-investors-partners/technology-portfolio/improved-cell-culture-media-derivation-and

Showing results 3001 - 3010 for Weill Cornell patient portal